地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察

目的观察地西他滨联合CAG方案治疗老年中高危MDS及AML的临床疗效及不良反应。方法应用地西他滨联合CAG方案治疗MDS及AML患者10例。1个疗程后评估疗效。结果10例患者，其中3例获得完全缓解（CR）30％，4例为部分缓解（PR）10％，1例获得骨髓缓解（mCR）40％。总有效率为80％。大多数患者出现了可以耐受的不良反应，主要表现为骨髓抑制。结论地西他滨联合CAG方案治疗中高危MDS和老年AML有较好的疗效和安全性。

Clinical study of CAG regimen combined Decitabine in treatment of elderly patients with moderate and high riskmyelodysplastic syndrome and acute myeloid leukemia

Objective To observe the clinical efficacy and adverse events of treatment for elderly patients with moderate and high-risk myelodysplastic syndrome （MDS） and acute myelocytic leukemia （ AML ） with Decitabine （25rag/d, dl-3） combined with CAG （G-CSF300ug/d, d4-13; aclarubicinl0mg/d, d4,6,8,10,12; Ara-C25mg/d, d4-13） regimen. Methods Decitabine combined with CAG regimen were used to treat 10 elderly patients with MDS and AML. The outcome was evalu- ated after 1 course of treatment. Results For ten patients, 3/10 （30%） achieved completely remission （CR）, 4/10 （40%） marrow completely remission （mCR）, 1/10 （10%） partial remission （PR）. The overall response rate was 80%. Most patients can withstand adverse reactions occurred mainly for the arrest of bone marrow. Condusion In older patients, medium and high-risk MDS and AML treated with Decitabine combined with CAG regimen is safe and effective.